INNOHEP Drug Patent Profile
✉ Email this page to a colleague
When do Innohep patents expire, and what generic alternatives are available?
Innohep is a drug marketed by Leo Pharma As and is included in one NDA.
The generic ingredient in INNOHEP is tinzaparin sodium. There is one drug master file entry for this compound. Additional details are available on the tinzaparin sodium profile page.
Summary for INNOHEP
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 6 |
Clinical Trials: | 20 |
Patent Applications: | 744 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INNOHEP at DailyMed |
Recent Clinical Trials for INNOHEP
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Galician Research Group on Digestive Tumors | Phase 3 |
University Hospital, Linkoeping | Phase 2 |
Kalmar County Hospital | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for INNOHEP
US Patents and Regulatory Information for INNOHEP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Leo Pharma As | INNOHEP | tinzaparin sodium | INJECTABLE;INJECTION | 020484-001 | Jul 14, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |